Navigation Links
New Ion Trap Mass Spectrometers From Varian, Inc. Offer the Ultimate in Sensitive Detection and High Productivity
Date:3/31/2008

PALO ALTO, Calif., March 31, 2008 /PRNewswire-FirstCall/ -- Varian, Inc. (NasdaqGS: VARI) announced today its new 200-MS Series of ion trap mass spectrometers for GC/MS (gas chromatography/mass spectrometry). GC/MS is used by analytical chemists for the detection and characterization of compounds in samples from a variety of applications including environmental, toxicology, food safety and agriculture. The series comprises three instruments (210-MS, 220-MS and 240-MS) for use in applications from routine analysis to advanced research.

Both the 240-MS and the 220-MS are delivered with Varian's top of the line 450-GC gas chromatograph to ensure the highest level of analytical performance. The 240-MS delivers the highest full scan sensitivity available. A choice of ionization modes and MS/MS scanning options allows accurate identification and quantification of trace analytes even in the presence of complex matrices. This robust instrument is easy to maintain, making it equally suitable for use in both research and high-throughput environments.

The 220-MS is a flexible instrument that offers excellent analytical capabilities with CI (chemical ionization) and MS/MS options for increased sensitivity and selectivity in a range of configurations. The 210-MS, available with the new 431-GC, is an entry level GC/MS designed for routine, high-throughput laboratories that require sensitive detection for gas chromatography.

"The 200-MS series offers a range of choices for analytical chemists to match their specific requirements," said Martin O'Donoghue, Senior Vice President, Scientific Instruments, Varian, Inc. "Varian has a complete GC/MS solution for every user from researchers interested in detailed structural analysis to novice operators running samples in a high throughput analytical laboratory."

For more technical information about Varian's GC/MS instrumentation, please visit http://www.varianinc.com/products/

Varian, Inc. is a leading worldwide supplier of scientific instruments and vacuum technologies for life science and industrial applications. The company provides complete solutions, including instruments, vacuum products, laboratory consumable supplies, software, training and support through its global distribution and support systems. Varian, Inc. employs approximately 3,900 people worldwide and operates manufacturing facilities in North America, Europe and Asia Pacific. Varian, Inc. had fiscal year 2007 sales of $921 million, and its common stock is traded on the NASDAQ Global Select Market under the symbol, "VARI." Further information is available on the company's Web site: http://www.varianinc.com.

For More Information, Contact:

Public Relations

Varian, Inc.

650.424.3845

pr@varianinc.com


'/>"/>
SOURCE Varian, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New High Performance Gas Chromatographs and Analysis Solutions From Varian, Inc. Offer Enhanced Performance and Capabilities for More Applications
2. Varian, Inc. Board Authorizes New $100 Million Stock Repurchase Program
3. Varian, Inc. CEO to Speak at JPMorgan Healthcare Conference
4. Varian, Inc. Acquires Analogix Business
5. Varian, Inc. Offers New Products for the Rapid Purification of Synthetic Oligonucleotides.
6. Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
7. Hillenbrand Industries, Inc. Announces Expiration and Final Results of its Previously Announced Any and All Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009
8. Supporting Healthy Marriage Program Offered by Montefiore
9. SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc.
10. 2008 Social Security Report Offers Dire Warning
11. Hillenbrand Industries, Inc. Announces Pricing of Its Pending Any and All Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... NY (PRWEB) , ... January 20, 2017 , ... ... VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been produced ... with optimal conditions to perform during your workout. , After a successful launch ...
(Date:1/20/2017)... ... January 20, 2017 , ... “I Forgive You”: a fine examination of how God ... is the creation of published author, Stephen Miller, who, for over ten long years has ... to him. Born in Trinidad and Tobago, he has been serving the Lord for over ...
(Date:1/20/2017)... ... , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of ... the creation of published author, Gene Gaapf, a retired truck driver, and a long-time ... been writing since high school and have many different titles,” Gaapf mentions about his ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
(Date:1/19/2017)... ... 19, 2017 , ... This month, the CEO and Clinical Director of Sober ... rehab center in Delray Beach, Florida has been changed from Sober Living Outpatient to ... Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, but thousands of ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the fourth quarter of 2016 on Wednesday, February 15, 2017, after ... ... on Wednesday, February 15, 2017, during which management will discuss the ... activities. To participate in the conference call, please dial 1-888-771-4371 (domestic) ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)... BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical company ... additions to its senior leadership team: W. Douglas ... Daniel Geffken as interim Chief Financial Officer. In ... has been promoted to Chief Clinical Development Officer. ... Daniel to our management team, as both will be ...
Breaking Medicine Technology: